Pak­istan re­calls al­tered dose of Avastin; FDA re­jects Botanix gel

Plus, MC2’s new li­cens­ing deal with Re­gran­ion and AM-Phar­ma an­nounces a new CEO and work­force cuts.

Pak­istan re­calls al­tered Avastin

Pak­istan is pulling a dose …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.